S. Talbird

发表

A steady-state, population-based model to estimate the direct and indirect effects of pneumococcal vaccines.

A. Ismaila, T. Taylor, S. Talbird, 2010, Vaccine.

Review of cost-effectiveness analyses of varicella vaccination

J. Mauskopf, S. Talbird, H. K. Yang, 2015 .

Cost‐effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment‐naïve adults with HIV‐1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial

M. Fisher, E. Wilkins, S. Talbird, 2016, HIV medicine.

Cost-Effectiveness Analysis Of Tenofovir/Emtricitabine And Abacavir/Lamivudine In Combination With Efavirenz Or Atazanavir/Ritonavir For Treatment-Naive Adults With Hiv-1 Infection In The United Kingdom

M. Fisher, E. Wilkins, S. Talbird, 2014 .

Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States.

B. Sander, S. Talbird, A. Brogan, 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

US Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Treatment-Experienced, HIV-Infected Adults with Evidence of Protease Inhibitor Resistance Included in the TITAN Trial

J. Mauskopf, S. Talbird, A. Brogan, 2012, PharmacoEconomics.

The Cost-Effectiveness and Budget Impact of Ibalizumab-uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States

S. Talbird, Princy N. Kumar, A. Brogan, 2021, PharmacoEconomics.

Budget impact analysis of multiple varicella vaccination strategies: a Mexico perspective

L. Wolfson, H. Monsanto, M. Pillsbury, 2019, Human vaccines & immunotherapeutics.

Impact of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine use in wound management on health care costs and pertussis cases.

G. Krishnarajah, J. Mauskopf, C. Masseria, 2015, Journal of managed care & specialty pharmacy.

Residual economic burden of Streptococcus pneumoniae- and nontypeable Haemophilus influenzae-associated disease following vaccination with PCV-7: a multicountry analysis.

A. Ismaila, T. Taylor, J. Caporale, 2010, Vaccine.

Impact of population aging on the burden of vaccine-preventable diseases among older adults in the United States

C. Hogea, S. Poston, Jessica K. DeMartino, 2020, Human vaccines & immunotherapeutics.

Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection

J. Mauskopf, S. Talbird, A. Brogan, 2012, AIDS.

Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.

C. Cohen, S. Talbird, A. Brogan, 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Antiseizure medications and oral contraceptives: Impact of enzyme inducers on pregnancy outcomes and costs

J. Mauskopf, M. Srinivasan, Annesha White, 2021, Epilepsy & Behavior.

Oseltamivir for influenza postexposure prophylaxis: economic evaluation for children aged 1-12 years in the U.S.

S. Talbird, A. Brogan, A. Winiarski, 2009, American journal of preventive medicine.

Cost per Responder Analysis for Pegcetacoplan and Eculizumab in the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinuria

S. Talbird, J. Fishman, Seri Anderson, 2021, Blood.

Is increased screening and early antiretroviral treatment for HIV‐1 worth the investment? An analysis of the public health and economic impact of improvement in the UK

D. Flanagan, S. Talbird, A. Brogan, 2019, HIV medicine.

Understanding the role of exogenous boosting in modeling varicella vaccination

J. Mauskopf, L. Wolfson, S. Talbird, 2018, Expert review of vaccines.

Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries.

T. Taylor, S. García Martí, S. Talbird, 2010, Vaccine.

Constrained Optimization for the Selection of Influenza Vaccines to Maximize the Population Benefit: A Demonstration Project

Baudouin Standaert, Ilse Van Vlaenderen, Laure-Anne Van Bellinghen, 2019, Applied Health Economics and Health Policy.

Achieving the Millennium Development Goals: the contribution of fulfilling the unmet need for family planning.

S. Talbird, S. Moreland, 2006 .

Reply to Strutton et al.: Response to “Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries”:

T. Taylor, William P. Hausdorff, S. Talbird, 2011 .

Targeted preventive vaccination campaigns to reduce Ebola outbreaks: An individual-based modeling study.

D. Bisanzio, M. Gaudig, T. V. Van Effelterre, 2022, Vaccine.

Cost-effectiveness of Telaprevir Combination Therapy for Chronic Hepatitis C

Jeffrey D. Miller, S. Talbird, A. Brogan, 2014, PloS one.

Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease

J. Fain, S. Talbird, Amit Srivastava, 2019, Human vaccines & immunotherapeutics.

Cost-effectiveness of a 3-antigen versus single-antigen vaccine for the prevention of hepatitis B in adults in the United States.

F. Diaz-Mitoma, S. Talbird, A. Rak, 2023, Vaccine.

Macroeconomic impact of Ebola outbreaks in Sub-Saharan Africa and potential mitigation of GDP loss with prophylactic Ebola vaccination programs

A. Honeycutt, S. Talbird, P. Macdonald, 2023, PloS one.

Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approach

E. Thommes, G. Meier, S. Talbird, 2016, Human vaccines & immunotherapeutics.

IN3 Translating Outcomes from a Dynamic Transmission Model for Varicella Vaccination to Cost-Effectiveness Estimates: The Impact of Different Analytic Approaches on the Results

J. Mauskopf, B. Standaert, S. Talbird, 2012 .

Cost-benefit analysis of vaccination against four preventable diseases in older adults: Impact of an aging population.

C. Hogea, S. Poston, Jessica K. DeMartino, 2021, Vaccine.

Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States.

V. Shinde, S. Talbird, B. Rosen, 2021, Vaccine.

Public health impact and return on investment of Belgium’s pediatric immunization program

S. Simoens, M. Van Ranst, J. Vandenhaute, 2023, Frontiers in Public Health.

Categorization of methods used in cost–effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models

J. Mauskopf, B. Standaert, S. Talbird, 2012, Expert review of pharmacoeconomics & outcomes research.

Modelling the effect of conjugate vaccines in pneumococcal disease: cohort or population models?

J. Mauskopf, B. Standaert, N. Demarteau, 2010, Vaccine.

Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection

J. Mauskopf, S. Talbird, A. Brogan, 2012, AIDS.

Value of the Immunization Program for Children in the 2017 US Birth Cohort.

G. Marshall, C. Carias, S. Talbird, 2022, Pediatrics.

Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease

J. Fain, S. Talbird, Amit Srivastava, 2019, Human vaccines & immunotherapeutics.

Expert Review of Pharmacoeconomics & Outcomes Research

J. Mauskopf, B. Standaert, S. Talbird, 2012 .

PIN8 BUDGET-IMPACT ANALYSIS OF ADDING THE NEW 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION (PHID-CV) TO ROUTINE INFANT VACCINATION IN CANADA

A. Ismaila, N. Rawson, B. Standaert, 2009 .

Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States.

B. Sander, S. Talbird, A. Brogan, 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.